1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Avalon, GSK launch latest slate of biotechs

 
• By Lisa LaMotta

In just about two years, Avalon Ventures and GlaxoSmithKline have launched six new biotechs with the promise of four more in the near future. The latest companies to be launched under the collaboration include Adrenergics, CadheRx Therapeutics and Calporta Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Boehringer Boss Talks Tariffs And State Of Play In The US

 
• By Kevin Grogan

The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By Kevin Grogan

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.